Mehra, who also chaired Abbott's ARIES-HM3 study in LVAD patients and is a Professor of Medicine, Harvard University, commented, "In the proposed TECH-LVAD trial, we plan to study a much-needed ...

(PRNewsfoto/Cadrenal Therapeutics, Inc.) Dr. Mehra, who also chaired Abbott's ARIES-HM3 study in LVAD patients and is a Professor of Medicine, Harvard University, commented, "In the proposed TECH-LVAD ...